img

Global and United States Oral Hypoglycemic Medications Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Oral Hypoglycemic Medications Market Report & Forecast 2024-2034

Oral Hypoglycemic Medications are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes.
Market Analysis and InsightsGlobal and United States Oral Hypoglycemic Medications Market
This report focuses on global and United States Oral Hypoglycemic Medications market, also covers the segmentation data of other regions in regional level and county level.
The global Oral Hypoglycemic Medications revenue was US$ 61200 million in 2024 and is forecast to a readjusted size of US$ 105950 million by 2034 with a CAGR of 8.7% during the forecast period (2024-2034).
In United States the Oral Hypoglycemic Medications revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Oral Hypoglycemic Medications include Bayer, Merck, Novartis, Huadong Medicine, Sanofi, Novo Nordisk, Servier, Takeda Pharmaceutical and Luye Pharmaceutical, etc. The global five biggest players hold a share of % in 2024.
Global Oral Hypoglycemic Medications Scope and Market Size
Oral Hypoglycemic Medications market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Oral Hypoglycemic Medications market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Oral Hypoglycemic Medications market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Bayer
Merck
Novartis
Huadong Medicine
Sanofi
Novo Nordisk
Servier
Takeda Pharmaceutical
Luye Pharmaceutical
Taiji Group
CR Double-Crane
AstraZeneca
Boehringer Ingelheim
Qilu Pharmaceutical
Jiangsu Deyuan Pharmaceutical
CTTQ
Segment by Type
Biguanides
Sulfonylureas
Meglitinides
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
SGLT2 Inhibitors
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Other

Segment by Application


Hospital
Clinic
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Oral Hypoglycemic Medications definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Oral Hypoglycemic Medications companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Oral Hypoglycemic Medications in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Hypoglycemic Medications sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Oral Hypoglycemic Medications Product Introduction
1.2 Global Oral Hypoglycemic Medications Outlook 2018 VS 2024 VS 2034
1.2.1 Global Oral Hypoglycemic Medications Sales in US$ Million for the Year 2018-2034
1.2.2 Global Oral Hypoglycemic Medications Sales in Volume for the Year 2018-2034
1.3 United States Oral Hypoglycemic Medications Outlook 2018 VS 2024 VS 2034
1.3.1 United States Oral Hypoglycemic Medications Sales in US$ Million for the Year 2018-2034
1.3.2 United States Oral Hypoglycemic Medications Sales in Volume for the Year 2018-2034
1.4 Oral Hypoglycemic Medications Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of United States Oral Hypoglycemic Medications in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Oral Hypoglycemic Medications Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.5 Oral Hypoglycemic Medications Market Dynamics
1.5.1 Oral Hypoglycemic Medications Industry Trends
1.5.2 Oral Hypoglycemic Medications Market Drivers
1.5.3 Oral Hypoglycemic Medications Market Challenges
1.5.4 Oral Hypoglycemic Medications Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Oral Hypoglycemic Medications by Type
2.1 Oral Hypoglycemic Medications Market Segment by Type
2.1.1 Biguanides
2.1.2 Sulfonylureas
2.1.3 Meglitinides
2.1.4 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.1.5 SGLT2 Inhibitors
2.1.6 Thiazolidinediones
2.1.7 Alpha-Glucosidase Inhibitors
2.1.8 Other
2.2 Global Oral Hypoglycemic Medications Market Size by Type
2.2.1 Global Oral Hypoglycemic Medications Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Oral Hypoglycemic Medications Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Oral Hypoglycemic Medications Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 United States Oral Hypoglycemic Medications Market Size by Type
2.3.1 United States Oral Hypoglycemic Medications Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 United States Oral Hypoglycemic Medications Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 United States Oral Hypoglycemic Medications Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Oral Hypoglycemic Medications by Application
3.1 Oral Hypoglycemic Medications Market Segment by Application
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Oral Hypoglycemic Medications Market Size by Application
3.2.1 Global Oral Hypoglycemic Medications Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Oral Hypoglycemic Medications Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Oral Hypoglycemic Medications Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 United States Oral Hypoglycemic Medications Market Size by Application
3.3.1 United States Oral Hypoglycemic Medications Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 United States Oral Hypoglycemic Medications Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 United States Oral Hypoglycemic Medications Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Oral Hypoglycemic Medications Competitor Landscape by Company
4.1 Global Oral Hypoglycemic Medications Market Size by Company
4.1.1 Global Key Manufacturers of Oral Hypoglycemic Medications, Ranked by Revenue (2024)
4.1.2 Global Oral Hypoglycemic Medications Revenue by Manufacturer (2018-2023)
4.1.3 Global Oral Hypoglycemic Medications Sales by Manufacturer (2018-2023)
4.1.4 Global Oral Hypoglycemic Medications Price by Manufacturer (2018-2023)
4.2 Global Oral Hypoglycemic Medications Concentration Ratio (CR)
4.2.1 Oral Hypoglycemic Medications Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Oral Hypoglycemic Medications in 2024
4.2.3 Global Oral Hypoglycemic Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Oral Hypoglycemic Medications, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Oral Hypoglycemic Medications, Product Offered and Application
4.5 Global Key Manufacturers of Oral Hypoglycemic Medications, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States Oral Hypoglycemic Medications Market Size by Company
4.7.1 Key Players of Oral Hypoglycemic Medications in United States, Ranked by Revenue (2024)
4.7.2 United States Oral Hypoglycemic Medications Revenue by Players (2018-2023)
4.7.3 United States Oral Hypoglycemic Medications Sales by Players (2018-2023)
5 Global Oral Hypoglycemic Medications Market Size by Region
5.1 Global Oral Hypoglycemic Medications Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Oral Hypoglycemic Medications Market Size in Volume by Region (2018-2034)
5.2.1 Global Oral Hypoglycemic Medications Sales in Volume by Region: 2018-2023
5.2.2 Global Oral Hypoglycemic Medications Sales in Volume Forecast by Region (2024-2034)
5.3 Global Oral Hypoglycemic Medications Market Size in Value by Region (2018-2034)
5.3.1 Global Oral Hypoglycemic Medications Sales in Value by Region: 2018-2023
5.3.2 Global Oral Hypoglycemic Medications Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Oral Hypoglycemic Medications Market Size YoY Growth 2018-2034
6.2 Americas Oral Hypoglycemic Medications Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Oral Hypoglycemic Medications Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Oral Hypoglycemic Medications Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Oral Hypoglycemic Medications Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Oral Hypoglycemic Medications Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Oral Hypoglycemic Medications Market Size YoY Growth 2018-2034
7.2 EMEA Oral Hypoglycemic Medications Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Oral Hypoglycemic Medications Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Oral Hypoglycemic Medications Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Oral Hypoglycemic Medications Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Oral Hypoglycemic Medications Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Oral Hypoglycemic Medications Market Size YoY Growth 2018-2034
8.2 China Oral Hypoglycemic Medications Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Oral Hypoglycemic Medications Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Oral Hypoglycemic Medications Market Size YoY Growth 2018-2034
9.2 APAC Oral Hypoglycemic Medications Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Oral Hypoglycemic Medications Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Oral Hypoglycemic Medications Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Oral Hypoglycemic Medications Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Oral Hypoglycemic Medications Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Bayer
10.1.1 Bayer Company Information
10.1.2 Bayer Description and Business Overview
10.1.3 Bayer Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bayer Oral Hypoglycemic Medications Products Offered
10.1.5 Bayer Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Description and Business Overview
10.2.3 Merck Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck Oral Hypoglycemic Medications Products Offered
10.2.5 Merck Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Description and Business Overview
10.3.3 Novartis Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Oral Hypoglycemic Medications Products Offered
10.3.5 Novartis Recent Development
10.4 Huadong Medicine
10.4.1 Huadong Medicine Company Information
10.4.2 Huadong Medicine Description and Business Overview
10.4.3 Huadong Medicine Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Huadong Medicine Oral Hypoglycemic Medications Products Offered
10.4.5 Huadong Medicine Recent Development
10.5 Sanofi
10.5.1 Sanofi Company Information
10.5.2 Sanofi Description and Business Overview
10.5.3 Sanofi Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Sanofi Oral Hypoglycemic Medications Products Offered
10.5.5 Sanofi Recent Development
10.6 Novo Nordisk
10.6.1 Novo Nordisk Company Information
10.6.2 Novo Nordisk Description and Business Overview
10.6.3 Novo Nordisk Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Novo Nordisk Oral Hypoglycemic Medications Products Offered
10.6.5 Novo Nordisk Recent Development
10.7 Servier
10.7.1 Servier Company Information
10.7.2 Servier Description and Business Overview
10.7.3 Servier Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Servier Oral Hypoglycemic Medications Products Offered
10.7.5 Servier Recent Development
10.8 Takeda Pharmaceutical
10.8.1 Takeda Pharmaceutical Company Information
10.8.2 Takeda Pharmaceutical Description and Business Overview
10.8.3 Takeda Pharmaceutical Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Takeda Pharmaceutical Oral Hypoglycemic Medications Products Offered
10.8.5 Takeda Pharmaceutical Recent Development
10.9 Luye Pharmaceutical
10.9.1 Luye Pharmaceutical Company Information
10.9.2 Luye Pharmaceutical Description and Business Overview
10.9.3 Luye Pharmaceutical Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Luye Pharmaceutical Oral Hypoglycemic Medications Products Offered
10.9.5 Luye Pharmaceutical Recent Development
10.10 Taiji Group
10.10.1 Taiji Group Company Information
10.10.2 Taiji Group Description and Business Overview
10.10.3 Taiji Group Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Taiji Group Oral Hypoglycemic Medications Products Offered
10.10.5 Taiji Group Recent Development
10.11 CR Double-Crane
10.11.1 CR Double-Crane Company Information
10.11.2 CR Double-Crane Description and Business Overview
10.11.3 CR Double-Crane Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.11.4 CR Double-Crane Oral Hypoglycemic Medications Products Offered
10.11.5 CR Double-Crane Recent Development
10.12 AstraZeneca
10.12.1 AstraZeneca Company Information
10.12.2 AstraZeneca Description and Business Overview
10.12.3 AstraZeneca Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.12.4 AstraZeneca Oral Hypoglycemic Medications Products Offered
10.12.5 AstraZeneca Recent Development
10.13 Boehringer Ingelheim
10.13.1 Boehringer Ingelheim Company Information
10.13.2 Boehringer Ingelheim Description and Business Overview
10.13.3 Boehringer Ingelheim Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Boehringer Ingelheim Oral Hypoglycemic Medications Products Offered
10.13.5 Boehringer Ingelheim Recent Development
10.14 Qilu Pharmaceutical
10.14.1 Qilu Pharmaceutical Company Information
10.14.2 Qilu Pharmaceutical Description and Business Overview
10.14.3 Qilu Pharmaceutical Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Qilu Pharmaceutical Oral Hypoglycemic Medications Products Offered
10.14.5 Qilu Pharmaceutical Recent Development
10.15 Jiangsu Deyuan Pharmaceutical
10.15.1 Jiangsu Deyuan Pharmaceutical Company Information
10.15.2 Jiangsu Deyuan Pharmaceutical Description and Business Overview
10.15.3 Jiangsu Deyuan Pharmaceutical Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Jiangsu Deyuan Pharmaceutical Oral Hypoglycemic Medications Products Offered
10.15.5 Jiangsu Deyuan Pharmaceutical Recent Development
10.16 CTTQ
10.16.1 CTTQ Company Information
10.16.2 CTTQ Description and Business Overview
10.16.3 CTTQ Oral Hypoglycemic Medications Sales, Revenue and Gross Margin (2018-2023)
10.16.4 CTTQ Oral Hypoglycemic Medications Products Offered
10.16.5 CTTQ Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Oral Hypoglycemic Medications Industry Chain Analysis
11.2 Oral Hypoglycemic Medications Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Oral Hypoglycemic Medications Production Mode & Process
11.4 Oral Hypoglycemic Medications Sales and Marketing
11.4.1 Oral Hypoglycemic Medications Sales Channels
11.4.2 Oral Hypoglycemic Medications Distributors
11.5 Oral Hypoglycemic Medications Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Oral Hypoglycemic Medications CAGR in Value, United States VS Global, 2018 VS 2024 VS 2034
Table 2. Oral Hypoglycemic Medications Market Trends
Table 3. Oral Hypoglycemic Medications Market Drivers
Table 4. Oral Hypoglycemic Medications Market Challenges
Table 5. Oral Hypoglycemic Medications Market Restraints
Table 6. Global Oral Hypoglycemic Medications Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Oral Hypoglycemic Medications Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Oral Hypoglycemic Medications Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Oral Hypoglycemic Medications Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Oral Hypoglycemic Medications, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Oral Hypoglycemic Medications Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Oral Hypoglycemic Medications Revenue Share by Manufacturer, 2018-2023
Table 13. Global Oral Hypoglycemic Medications Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Oral Hypoglycemic Medications Sales Share by Manufacturer, 2018-2023
Table 15. Global Oral Hypoglycemic Medications Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Oral Hypoglycemic Medications Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Oral Hypoglycemic Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Hypoglycemic Medications as of 2024)
Table 18. Global Key Manufacturers of Oral Hypoglycemic Medications, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Oral Hypoglycemic Medications, Product Offered and Application
Table 20. Global Key Manufacturers of Oral Hypoglycemic Medications, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Oral Hypoglycemic Medications in United States, Ranked by Revenue (2024) & (US$ million)
Table 23. United States Oral Hypoglycemic Medications Revenue by Players, (US$ Million), (2018-2023)
Table 24. United States Oral Hypoglycemic Medications Revenue Share by Players, (2018-2023)
Table 25. United States Oral Hypoglycemic Medications Sales by Players, (K Units), (2018-2023)
Table 26. United States Oral Hypoglycemic Medications Sales Share by Players, (2018-2023)
Table 27. Global Oral Hypoglycemic Medications Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Oral Hypoglycemic Medications Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Oral Hypoglycemic Medications Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Oral Hypoglycemic Medications Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Oral Hypoglycemic Medications Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Oral Hypoglycemic Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Oral Hypoglycemic Medications Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Oral Hypoglycemic Medications Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Oral Hypoglycemic Medications Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Oral Hypoglycemic Medications Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Oral Hypoglycemic Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Oral Hypoglycemic Medications Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Oral Hypoglycemic Medications Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Oral Hypoglycemic Medications Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Oral Hypoglycemic Medications Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Oral Hypoglycemic Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Oral Hypoglycemic Medications Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Oral Hypoglycemic Medications Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Oral Hypoglycemic Medications Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Oral Hypoglycemic Medications Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Bayer Company Information
Table 48. Bayer Description and Business Overview
Table 49. Bayer Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. Bayer Oral Hypoglycemic Medications Product
Table 51. Bayer Recent Development
Table 52. Merck Company Information
Table 53. Merck Description and Business Overview
Table 54. Merck Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Merck Oral Hypoglycemic Medications Product
Table 56. Merck Recent Development
Table 57. Novartis Company Information
Table 58. Novartis Description and Business Overview
Table 59. Novartis Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Novartis Oral Hypoglycemic Medications Product
Table 61. Novartis Recent Development
Table 62. Huadong Medicine Company Information
Table 63. Huadong Medicine Description and Business Overview
Table 64. Huadong Medicine Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Huadong Medicine Oral Hypoglycemic Medications Product
Table 66. Huadong Medicine Recent Development
Table 67. Sanofi Company Information
Table 68. Sanofi Description and Business Overview
Table 69. Sanofi Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Sanofi Oral Hypoglycemic Medications Product
Table 71. Sanofi Recent Development
Table 72. Novo Nordisk Company Information
Table 73. Novo Nordisk Description and Business Overview
Table 74. Novo Nordisk Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Novo Nordisk Oral Hypoglycemic Medications Product
Table 76. Novo Nordisk Recent Development
Table 77. Servier Company Information
Table 78. Servier Description and Business Overview
Table 79. Servier Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Servier Oral Hypoglycemic Medications Product
Table 81. Servier Recent Development
Table 82. Takeda Pharmaceutical Company Information
Table 83. Takeda Pharmaceutical Description and Business Overview
Table 84. Takeda Pharmaceutical Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Takeda Pharmaceutical Oral Hypoglycemic Medications Product
Table 86. Takeda Pharmaceutical Recent Development
Table 87. Luye Pharmaceutical Company Information
Table 88. Luye Pharmaceutical Description and Business Overview
Table 89. Luye Pharmaceutical Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Luye Pharmaceutical Oral Hypoglycemic Medications Product
Table 91. Luye Pharmaceutical Recent Development
Table 92. Taiji Group Company Information
Table 93. Taiji Group Description and Business Overview
Table 94. Taiji Group Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Taiji Group Oral Hypoglycemic Medications Product
Table 96. Taiji Group Recent Development
Table 97. CR Double-Crane Company Information
Table 98. CR Double-Crane Description and Business Overview
Table 99. CR Double-Crane Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. CR Double-Crane Oral Hypoglycemic Medications Product
Table 101. CR Double-Crane Recent Development
Table 102. AstraZeneca Company Information
Table 103. AstraZeneca Description and Business Overview
Table 104. AstraZeneca Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. AstraZeneca Oral Hypoglycemic Medications Product
Table 106. AstraZeneca Recent Development
Table 107. Boehringer Ingelheim Company Information
Table 108. Boehringer Ingelheim Description and Business Overview
Table 109. Boehringer Ingelheim Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Boehringer Ingelheim Oral Hypoglycemic Medications Product
Table 111. Boehringer Ingelheim Recent Development
Table 112. Qilu Pharmaceutical Company Information
Table 113. Qilu Pharmaceutical Description and Business Overview
Table 114. Qilu Pharmaceutical Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Qilu Pharmaceutical Oral Hypoglycemic Medications Product
Table 116. Qilu Pharmaceutical Recent Development
Table 117. Jiangsu Deyuan Pharmaceutical Company Information
Table 118. Jiangsu Deyuan Pharmaceutical Description and Business Overview
Table 119. Jiangsu Deyuan Pharmaceutical Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Jiangsu Deyuan Pharmaceutical Oral Hypoglycemic Medications Product
Table 121. Jiangsu Deyuan Pharmaceutical Recent Development
Table 122. CTTQ Company Information
Table 123. CTTQ Description and Business Overview
Table 124. CTTQ Oral Hypoglycemic Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. CTTQ Oral Hypoglycemic Medications Product
Table 126. CTTQ Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Oral Hypoglycemic Medications Customers List
Table 130. Oral Hypoglycemic Medications Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Oral Hypoglycemic Medications Product Picture
Figure 2. Global Oral Hypoglycemic Medications Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Oral Hypoglycemic Medications Market Size 2018-2034 (US$ Million)
Figure 4. Global Oral Hypoglycemic Medications Sales 2018-2034 (K Units)
Figure 5. United States Oral Hypoglycemic Medications Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. United States Oral Hypoglycemic Medications Market Size 2018-2034 (US$ Million)
Figure 7. United States Oral Hypoglycemic Medications Sales 2018-2034 (K Units)
Figure 8. United States Oral Hypoglycemic Medications Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. United States Oral Hypoglycemic Medications Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Oral Hypoglycemic Medications Report Years Considered
Figure 11. Product Picture of Biguanides
Figure 12. Product Picture of Sulfonylureas
Figure 13. Product Picture of Meglitinides
Figure 14. Product Picture of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Figure 15. Product Picture of SGLT2 Inhibitors
Figure 16. Product Picture of Thiazolidinediones
Figure 17. Product Picture of Alpha-Glucosidase Inhibitors
Figure 18. Product Picture of Other
Figure 19. Global Oral Hypoglycemic Medications Market Share by Type in 2024 & 2034
Figure 20. Global Oral Hypoglycemic Medications Sales in Value by Type (2018-2034) & (US$ Million)
Figure 21. Global Oral Hypoglycemic Medications Sales Market Share in Value by Type (2018-2034)
Figure 22. Global Oral Hypoglycemic Medications Sales by Type (2018-2034) & (K Units)
Figure 23. Global Oral Hypoglycemic Medications Sales Market Share in Volume by Type (2018-2034)
Figure 24. Global Oral Hypoglycemic Medications Price by Type (2018-2034) & (US$/Unit)
Figure 25. United States Oral Hypoglycemic Medications Market Share by Type in 2024 & 2034
Figure 26. United States Oral Hypoglycemic Medications Sales in Value by Type (2018-2034) & (US$ Million)
Figure 27. United States Oral Hypoglycemic Medications Sales Market Share in Value by Type (2018-2034)
Figure 28. United States Oral Hypoglycemic Medications Sales by Type (2018-2034) & (K Units)
Figure 29. United States Oral Hypoglycemic Medications Sales Market Share in Volume by Type (2018-2034)
Figure 30. United States Oral Hypoglycemic Medications Price by Type (2018-2034) & (US$/Unit)
Figure 31. Product Picture of Hospital
Figure 32. Product Picture of Clinic
Figure 33. Product Picture of Other
Figure 34. Global Oral Hypoglycemic Medications Market Share by Application in 2024 & 2034
Figure 35. Global Oral Hypoglycemic Medications Sales in Value by Application (2018-2034) & (US$ Million)
Figure 36. Global Oral Hypoglycemic Medications Sales Market Share in Value by Application (2018-2034)
Figure 37. Global Oral Hypoglycemic Medications Sales by Application (2018-2034) & (K Units)
Figure 38. Global Oral Hypoglycemic Medications Sales Market Share in Volume by Application (2018-2034)
Figure 39. Global Oral Hypoglycemic Medications Price by Application (2018-2034) & (US$/Unit)
Figure 40. United States Oral Hypoglycemic Medications Market Share by Application in 2024 & 2034
Figure 41. United States Oral Hypoglycemic Medications Sales in Value by Application (2018-2034) & (US$ Million)
Figure 42. United States Oral Hypoglycemic Medications Sales Market Share in Value by Application (2018-2034)
Figure 43. United States Oral Hypoglycemic Medications Sales by Application (2018-2034) & (K Units)
Figure 44. United States Oral Hypoglycemic Medications Sales Market Share in Volume by Application (2018-2034)
Figure 45. United States Oral Hypoglycemic Medications Price by Application (2018-2034) & (US$/Unit)
Figure 46. Americas Oral Hypoglycemic Medications Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 47. Americas Oral Hypoglycemic Medications Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 48. Americas Oral Hypoglycemic Medications Sales by Type (2018-2034) & (K Units)
Figure 49. Americas Oral Hypoglycemic Medications Sales Market Share in Volume by Type (2018-2034)
Figure 50. Americas Oral Hypoglycemic Medications Sales by Application (2018-2034) & (K Units)
Figure 51. Americas Oral Hypoglycemic Medications Sales Market Share in Volume by Application (2018-2034)
Figure 52. United States Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 53. Canada Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 54. Mexico Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 55. Brazil Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 56. EMEA Oral Hypoglycemic Medications Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 57. EMEA Oral Hypoglycemic Medications Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 58. EMEA Oral Hypoglycemic Medications Sales by Type (2018-2034) & (K Units)
Figure 59. EMEA Oral Hypoglycemic Medications Sales Market Share in Volume by Type (2018-2034)
Figure 60. EMEA Oral Hypoglycemic Medications Sales by Application (2018-2034) & (K Units)
Figure 61. EMEA Oral Hypoglycemic Medications Sales Market Share in Volume by Application (2018-2034)
Figure 62. Europe Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 63. Middle East Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 64. Africa Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 65. China Oral Hypoglycemic Medications Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 66. China Oral Hypoglycemic Medications Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 67. China Oral Hypoglycemic Medications Sales by Type (2018-2034) & (K Units)
Figure 68. China Oral Hypoglycemic Medications Sales Market Share in Volume by Type (2018-2034)
Figure 69. China Oral Hypoglycemic Medications Sales by Application (2018-2034) & (K Units)
Figure 70. China Oral Hypoglycemic Medications Sales Market Share in Volume by Application (2018-2034)
Figure 71. APAC Oral Hypoglycemic Medications Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 72. APAC Oral Hypoglycemic Medications Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 73. APAC Oral Hypoglycemic Medications Sales by Type (2018-2034) & (K Units)
Figure 74. APAC Oral Hypoglycemic Medications Sales Market Share in Volume by Type (2018-2034)
Figure 75. APAC Oral Hypoglycemic Medications Sales by Application (2018-2034) & (K Units)
Figure 76. APAC Oral Hypoglycemic Medications Sales Market Share in Volume by Application (2018-2034)
Figure 77. Japan Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 78. South Korea Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 79. China Taiwan Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 81. India Oral Hypoglycemic Medications Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 82. Oral Hypoglycemic Medications Value Chain
Figure 83. Oral Hypoglycemic Medications Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries